Shares of OptiNose Inc (NASDAQ:OPTN) have been assigned an average broker rating score of 1.33 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a buy rating and two have issued a strong buy rating on the company.

Analysts have set a twelve-month consensus price objective of $29.67 for the company and are expecting that the company will post ($0.46) EPS for the current quarter, according to Zacks. Zacks has also given OptiNose an industry rank of 169 out of 265 based on the ratings given to related companies.

A number of equities research analysts recently weighed in on the stock. Royal Bank of Canada assumed coverage on shares of OptiNose in a research note on Tuesday, November 7th. They issued an “outperform” rating and a $33.00 target price on the stock. Jefferies Group assumed coverage on shares of OptiNose in a research note on Tuesday, November 7th. They issued a “buy” rating and a $27.00 target price on the stock. BMO Capital Markets assumed coverage on shares of OptiNose in a research note on Tuesday, November 7th. They issued an “outperform” rating and a $29.00 target price on the stock. Finally, Piper Jaffray Companies assumed coverage on shares of OptiNose in a research note on Tuesday, November 7th. They issued an “overweight” rating and a $27.00 target price on the stock.

Shares of OptiNose (NASDAQ OPTN) traded up $0.34 on Wednesday, reaching $18.02. 57,900 shares of the company were exchanged, compared to its average volume of 62,167. The stock has a market capitalization of $650.46 and a P/E ratio of -3.38. OptiNose has a 1-year low of $15.01 and a 1-year high of $21.46.

TRADEMARK VIOLATION WARNING: This piece of content was first published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/zacks-optinose-inc-optn-receives-average-recommendation-of-strong-buy-from-brokerages/1801266.html.

OptiNose Company Profile

OptiNose, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other.

Get a free copy of the Zacks research report on OptiNose (OPTN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.